Skip to main content
SpringerLink
Log in

Tolterodine Offers New Hope for Those with Overactive Bladder

  • New Drugs and Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Abrams P. Tolterodine: a viewpoint. Drugs 1998 Jun; 55 (6): 821

    Article  Google Scholar 

  2. Hills C, Winter SA, Balfour JA. Tolterodine. Drugs 1998 Jun; 55 (6): 813–20

    Article  CAS  Google Scholar 

  3. British National Formulary. No. 36. London: The Pharmaceutical Press, 1998 Sep: 361–2

  4. Nilvebrant L, Andersson K-E, Gillberg P-G, et al. Tolterodine — a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997 May 30; 327: 195–207

    Article  Google Scholar 

  5. PDR Generics. 5th ed. Montvale NJ: Medical Economics, 1999: 2477–80

  6. ABPI compendium of data sheets and summaries of product characteristics 1998–99. London: Datapharma Publications Ltd, 1998: 673–4, 983–5

  7. Martindale. The Extra Pharmacopoeia, 31st ed. London: Pharmaceutical Press, 1996: 504

    Google Scholar 

  8. 1997 Physicians GenRx. St Louis, Missouri: Mosby-Year Book, Inc., 1997: 504–5

  9. Abrams P, Freeman R, Anderstrom C, et al. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998 Jun; 81 (6): 801–10

    Article  PubMed  CAS  Google Scholar 

  10. Apell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997; 50 Suppl. 6A: 90–6

    Article  Google Scholar 

  11. Abrams P, Freeman RN, Anderstrom C, et al. Efficacy and tolerability of tolterodine vs. oxybutynin and placebo in patients with detrusor instability [abstract]. J Urol 1997 Apr; 157 Suppl.: 103

    Google Scholar 

  12. Drutz H, Appell RA. Clinical efficacy and safety of tolterodine vs oxybutynin and placebo in patients with unstable bladder [abstract). Acta Obstet Gynecol Scand 1997; 76: 24

    Google Scholar 

  13. Van Kerrebroeck PhEVA, Serment G, Dreher E. Clinical efficacy and safety of tolterodine compared to oxybutynin in patients with overactive bladder. Neurourol Urodyn 1997; 16: 478–9

    Google Scholar 

  14. Moore K, Millard R, Dwyer P, et al. A randomized controlled multicentre trial of tolterodine in detrusor instability! hyper-reflexia [abstract). Int Urogynecol J 1997; 8: S129

    Google Scholar 

  15. Clemett D. Tolterodine: improving QOL in patients with overactive bladder. Inpharma 1998 Jul 25; 1147: 7–8

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tolterodine Offers New Hope for Those with Overactive Bladder. Drugs Ther. Perspect 13, 1–4 (1999). https://doi.org/10.2165/00042310-199913060-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199913060-00001

Keywords

Search

Navigation